Sridharan BanuPriya, Sharma Blanka, Detamore Michael S
1 Bioengineering Program, University of Kansas , Lawrence, Kansas.
2 Department of Biomedical Engineering, University of Florida , Gainesville, Florida.
Tissue Eng Part B Rev. 2016 Feb;22(1):15-33. doi: 10.1089/ten.TEB.2015.0147. Epub 2015 Nov 5.
Despite numerous efforts in cartilage regeneration, few products see the light of clinical translation as the commercialization process is opaque, financially demanding, and requires collaboration with people of varied skill sets. The aim of this review is to introduce, to an academic audience, the different paradigms involved in the commercialization of cartilage regeneration technology, elucidate the different hurdles associated with the use of cells and materials in developing new technologies, discuss potential commercialization strategies, and inform the reader about the current trends observed in both the clinical and laboratory setting for establishing clinical trials. Although there are review articles on articular cartilage tissue engineering, independent reports provided by the Food and Drug Administration, and separate review articles on animal models, this is the first review that encompasses all of these facets and is presented in a format favorable to the academic investigator interested in clinical translation from bench to bedside.
尽管在软骨再生方面付出了诸多努力,但由于商业化过程不透明、资金需求大且需要与具备不同技能的人员合作,很少有产品能够实现临床转化。本综述的目的是向学术受众介绍软骨再生技术商业化所涉及的不同模式,阐明在开发新技术过程中使用细胞和材料所面临的各种障碍,讨论潜在的商业化策略,并让读者了解在临床和实验室环境中建立临床试验所观察到的当前趋势。虽然有关关节软骨组织工程的综述文章、美国食品药品监督管理局提供的独立报告以及关于动物模型的单独综述文章都存在,但这是第一篇涵盖所有这些方面且以有利于对从实验室到临床的临床转化感兴趣的学术研究人员的形式呈现的综述。